Otzuka, Bristol-Myers lose discovery bid in decade-old fight over Abilify

Allens 2021-04-27 4:46 pm By Christine Caulfield | Melbourne

Please login to bookmark

The companies behind the top selling Abilify medication have lost their latest bid for documents from the Commonwealth in a multimillion dollar dispute over the delayed listing of generic versions of their drug, with a judge saying the material could be only “of the most marginal relevance”.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au